Investigations of genetic polymorphisms related to Behçet’s disease in Turkish population: Behçet hastalığı ile ilgili Türk popülasyonundaki genetik polimorfizm araştırmaları

Elif Oğuz; Abdullah Tuncay Demiryürek; Belgin Alaşehirli; Ahmet Mesut Onat

doi:10.5455/GMJ-30-47080

Authors

Elif Oğuz Department of Medical Pharmacology, Faculty of Medicine, University of Harran, Şanlıurfa
Abdullah Tuncay Demiryürek Department of Medical Pharmacology, Faculty of Medicine, University of Gaziantep, Gaziantep
Belgin Alaşehirli Department of Medical Pharmacology, Faculty of Medicine, University of Gaziantep, Gaziantep
Ahmet Mesut Onat Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, University of Gaziantep

DOI:

https://doi.org/10.5455/GMJ-30-47080

Keywords:

Behçet’s disease; genetic association, polymorphism

Abstract

It is known that genetic variations are associated with some diseases and increase developing of some diseases while decrease some of them. The recent studies show that genetic polymorphisms have a role on susceptibility and prognosis of Behçet’s disease (BD). Knowing the polymorphisms associated with BD and the side of these associations will be useful for explaining the pathogenesis of the disease and to develop more effective therapies. In this review we aimed to overview the recent studies investigated the polimorphisms which may have a role in BD in Turkish population.

Metrics

Metrics Loading ...

References

Borlu M. Behçet hastalığında etyopatogenez. Erciyes Üniversitesi Sağlık Bilimleri Dergisi (Journal of Health Sciences) 2007;16(1):63-72.

Karaoğlan B. Behçet Hastalarında Klinik Bulgular ve Lokomotor Sistem Tutulumu. Turk J Phys Med Rehab 2008;54(1):34-7.

Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999;54(3):213- 20.

Gul A, Inanc¸ M, Ocal L, Aral O, Konic M. Familial aggregation of Behcet’s disease in Turkey. Ann Rheum Dis 2000;59(8):622-5.

Türsen Ü, Gürler A. Behçet hastalığı ve genetik. T Klin J Dermatol 2000;10(1):37-43.

Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol 1982;100(9):1455-8.

Zouboulis CC, Vaiopoulos G, Marcomichelakis N, Palimeris G, Markidou I, Thouas B, et al. Onset signs, clinical course,

prognosis, treatment and outcome of adult patients with Adamantiades-Behçet's disease in Greece. Clin Exp Rheumatol 2003;21(30):19-26.

Gül A, Hajeer AH, Worthington J, Barrett JH, Ollier WE, Silman AJ. Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001;44(1):239-40.

Mizuki N, Meguro A, Tohnai I, Gül A, Ohno S, Mizuki N. Association of major histocompatibility complex class I chain-related gene A and HLA-B alleles with Behçet's disease in Turkey. Jpn J Ophthalmol 2007;51(6):431-6.

Demirhindi O, Yazıcı H, Binyıldız P. Silivri Fener köyü yöresinde Behçet hastalığının sıklığı ve bu hastalığın toplum içerisinde taranmasında kullanılabilecek bir yöntem. Cerrahpaşa Tıp Fakültesi Dergisi 1981;12:509-14.

Yurdakul S, Günaydın İ, Tüzün Y. The prevelance of Behçet’s syndrome in rural area in Northern Turkey. J Rheumatol 1988;15(5):820-2.

Idil A, Gürler A, Boyvat A, Caliskan D, Ozdemir O, Isik A, et al. The prevalance of Behçet’s disease above the age of 10 years. The results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophtalmic Epidemiol 2002;9(5):325-33.

Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, et al. Prevalance of Behçet’s disease in İstanbul, Turkey. Int J Dermatol 2003;42(10):803-6.

Cakir N, Dervis E, Benian O, Pamuk ON, Sonmezates N, Rahimoglu R, et al. Prevalance of Behçet’s disease in rural Western Turkey: A preliminary report. Clin Exp Rheumatol 2004;22(34):53-5.

Zouboulis CC. Epidemiology of Adamantiades-Behcet's disease. Ann Med Interne (Paris) 1999;150(6):488-98.

Rizzi R, Bruno S, Dammacco R. Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes. Int J Clin Lab Res 1997;27(4):225-32.

Gül A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19(24):6-12.

Rajendram R, Rao NA. Molecular mechanisms in Behçet’s disease. Br J Ophthalmol 2003;87810):1199-200.

Nicholson LB, Kuchroo VK. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr Opin Immunol 1996;8(6):837-42.

Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S. Divergent cytokine production profile in Behçet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998;25(2):329–33.

Braun N, Michel U, Ernst BP, Metzner R, Bitsch A, Weber F, Rieckmann P. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production. Neurosci Lett 1996;215(2):75-8.

Wu WS, McClain KL. DNA polymorphisms and mutations of the tumor necrosis factor-alpha (TNF-alpha) promoter in

Langerhans cell histiocytosis (LCH). J Interferon Cytokine Res 1997;17(10):631-5.

Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosism factor a promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94(7):3195-9.

Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997;34(5):391-9.

Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, et al. TNF-alpha promoter

polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J. Neuroimmunol

;72(2):149-53.

Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, et al. Polymorphism of the 5'-flanking region of the human

tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998;51(6):605-12.

Duymaz-Tozkir J, Gül A, Uyar FA, Ozbek U, Saruhan- Direskeneli G. Tumour necrosis factor-alpha gene promoter region -308 and -376 G>A polymorphisms in Behçet's disease. Clin Exp Rheumatol 2003;21(30):15-8.

Ateş O, Dalyan L, Hatemi G, Hamuryudan V, Topal-Sarıkaya A. Analyses of functional IL10 and TNF-α genotypes in Behçet's syndrome. Mol Biol Rep 2010;37(7):3637-41.

Storz K, Löffler J, Koch S, Vonthein R, Zouboulis CC, Fresko I, et al. IL-6 receptor, IL-8 receptor and TNF-alpha238 (G/A) polymorphisms are not associated with Behçet's disease in patients of German or Turkish origin. Clin Exp Rheumatol 2008;26(4):103-6.

Akman A, Sallakci N, Coskun M, Bacanli A, Yavuzer U, Alpsoy E, et al. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behçet's disease. Br J Dermatol 2006;155(2):350-6.

Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24(1):1-8.

Ma SL, Tang NL, Lam LC, Chiu HF. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. Neurobiol Aging 2005;26(7):1005-10.

Dilek K, Ozçimen AA, Saricaoğlu H, Saba D, Yücel A, Yurtkuran M, et al. Cytokine gene polymorphisms in Behçet's disease and their association with clinical and laboratory findings. Clin Exp Rheumatol 2009;27(2):73-8.

Ateş A, Kinikli G, Düzgün N, Duman M. Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behçet's disease. Rheumatol Int 2006;26(4):348-53.

Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klinnert M, et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995;25(2):74-8.

Hershey, KG, Fredrich, MF, Esswein, LA, Thomas, ML, Chatila, TA. The association of atopy with a gain of function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997;337(20):1720-5.

Oral HB, Dilek K, Özçimen AA, Taşkapılıoğlu Ö, Bingöl Ü, Sarandöl A, et al. Interleukin-4 gene polymorphisms confer Behçet's disease in Turkish population. Scand J Immunol 2011;73(6):594-601.

Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity. Isr J Med Sci 1995;31(6):345-8.

Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16(5-6):457-99.

Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992;22(6):396-402.

Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 2006;15(4):519-29.

Ozçimen AA, Dilek K, Bingöl U, Sarıcaoğlu H, Sarandöl A, Taşkapılıoğlu O, et al. IL-1 cluster gene polymorphisms in Turkish patients with Behçet's disease. Int J Immunogenet 2011;38(4):295-301.

Akman A, Ekinci NC, Kacaroglu H, Yavuzer U, Alpsoy E, Yegin O. Relationship between periodontal findings and specific polymorphisms of interleukin-1alpha and -1beta in Turkish patients with Behçet's disease. Arch Dermatol Res 2008;300(1):19-26.

Beyaz F. T Lenfositerin gelişimi, fonksiyonları ve histokimyasal özellikleri. Erciyes Üniv Vet Fak Derg 2004;1(1):61-6.

Mäurer M, Loserth S, Kolb-Mäurer A, Ponath A, Wiese S, Kruse N, et al. A polymorphism in the human cytotoxic Tlymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters Tcell activation. Immunogenetics 2002;54(1):1-8.

Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001;2(3):45-52.

Seidl C, Donner H, Fischer B, Usadel KH, Seifried E, Kaltwasser JP, et al. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens 1998;51(1):62-6.

Ahmed S, Ihara K, Kanemitsu S, Nakashima H, Otsuka T, Tsuzaka K, et al. Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Rheumatology 2001;40(6):662-7.

Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J Immunol 2000;165(11):6606-11.

Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R, et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997;82(1):143-6.

Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E, Yegin O. CTLA-4 gene 49A/G polymorphism in Turkish patients with Behçet's disease. Clin Exp Dermatol 2005;30(5):546- 50.

Gunesacar R, Erken E, Bozkurt B, Ozer HT, Dinkci S, Erken EG, et al. Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet's disease. Int J Immunogenet 2007;34(1):45-9.

Düzgün N, Duman T, Keskin O, Morris Y, Tutkak H. Cytotoxic T lymphocyte antigen-4 (CTLA-4) polymorphism in patients with Behçet's disease. Clin Exp Rheumatol 2010;28(4 Suppl 60):S100.

Zhang YJ, Xu WD, Duan ZH, Liu SS, Pan HF, Ye DQ. Lack of association between CTLA-4 +49A/G and -318C/T polymorphisms and Behçet's disease risk: a meta-analysis. Clin Exp Rheumatol 2012;30(72):46-50.

Lee YH, Song GG. CTLA-4 polymorphisms and susceptibility to Behcet's disease: a meta-analysis. Mol Biol Rep 2012;39(9):9041-5.

Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275–90.

van der Pol W, van de Winkel JG. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998;48(3):222-32.

Li X, Ptacek TS, Brown EE, Edberg JC. Fcgamma receptors: structure, function and role as genetic risk factors in SLE. Genes Immun 2009;10(5):380-9.

Aksu K, Kitapcioglu G, Keser G, Berdeli A, Karabulut G, Kobak S, et al. FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behçet's disease: do they have any clinical implications? Clin Exp Rheumatol 2008;26(4):77-83.

Blackwell JM, Barton CH, White JK, Searle S, Baker AM, Williams H, et al. Genomic organization and sequence of the human NRAMP gene: identification and mapping of a promoter region polymorphism. Mol Med 1995;1(2):194- 205.

Blackwell JM, Searle S, Goswami T, Miller EN. Understanding the multiple functions of Nramp1. Microbes Infect 2000;2(3):317-21.

Searle S, Blackwell JM. Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious diseases. J Med Genet 1999;36(4):295-9.

Ateş O, Dalyan L, Hatemi G, Hamuryudan V, Topal-Sarikaya A. Genetic susceptibility to Behçet's syndrome is associated with NRAMP1 (SLC11A1) polymorphism in Turkish patients. Rheumatol Int 2009;29(7):787-91.

Anderson KV. Toll signaling pathways in the innate immune response. Curr Opin Immunol 2000;12(1):13-9.

Schröder NW, Hermann C, Hamann L, Göbel UB, Hartung T, Schumann RR. High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allelespecific PCR. J Mol Med (Berl) 2003;81(6):368-72.

Bacanli A, Sallakci N, Yavuzer U, Alpsoy E, Yegin O. Toll-like receptor 2 Arg753Gln gene polymorphism in Turkish patients with Behçet's disease. Clin Exp Dermatol 2006;31(5):699-701.

Coşan F, Oku B, Cakiris A, Duymaz-Tozkir J, Mercanoğlu F, Saruhan-Direskeneli G, et al. No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Behçet's disease. Clin Rheumatol 2009;28(12):1385-8.

Lesage S, Zouali H, Cézard JP, Colombel JF, Belaiche J, Almer S, et al. CARD15/NOD2 mutational analysis and genotype phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70(4):845-57.

Uyar FA, Saruhan-Direskeneli G, Gül A. Common Crohn's disease-predisposing variants of the CARD15/NOD2 gene are not associated with Behçet's disease in Turkey. Clin Exp Rheumatol 2004;22(34):50-2.

Fiorillo E, Orrú V, Stanford SM, Liu Y, Salek M, Rapini N, et al. Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue. Biol Chem 2010;285(34):26506-18.

Begovich AB, Carlton VEH, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, et al. A missense singlenucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004;75(2):330-7.

Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004;36(4):337-8.

Sahin N, Bicakcigil M, Atagunduz P, Direskeneli H, Saruhan- Direskeneli G. PTPN22 gene polymorphism in Behçet's disease. Tissue Antigens 2007;70(5):432-4.

Kritchevsky SB, Nicklas BJ, Visser M, Simonsick EM, Newman AB, Harris TB, et al. Angiotensin-converting enzyme insertion/deletion genotype, exercise, and physical decline. JAMA 2005;294(6):691-8.

Oztürk MA, Calgüneri M, Kiraz S, Ertenli I, Onat AM, Ureten K, et al. Angiotensin-converting enzyme gene polymorphism in Behçet's disease. Clin Rheumatol 2004;23(2):142-6.

Dursun A, Durakbasi-Dursun HG, Dursun R, Baris S, Akduman L. Angiotensin-converting enzyme gene and endothelial nitric oxide synthase gene polymorphisms in Behçet's disease with or without ocular involvement. Inflamm Res 2009;58(7):401-5.

Turgut S, Turgut G, Atalay EO, Atalay A. Angiotensinconverting enzyme I/D polymorphism in Behçet's disease. Med Princ Pract 2005;14(4):213-6.

Yigit S, Tural S, Rüstemoglu A, Inanir A, Gul U, Kalkan G, et al. DD genotype of ACE gene I/D polymorphism is associated with Behcet disease in a Turkish population. Mol Biol Rep 2013;40(1):365-8.

Yildirim M, Baysal V, Inaloz HS, Doguc D. The significance of serum nitric oxide levels in Behcet's disease and recurrent aphthous stomatitis. J Dermatol 2004;31(12):983-8.

Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flowdependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;1;91(5):1314-9.

Raza K, Thambyrajah J, Townend JN, Exley AR, Hortas C, Filer A, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000;102(13):1470-2.

Wang XL, Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab 2000;70(4):241-51.

Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T, Yoshimura M. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T-˃C mutation associated with coronary spastic angina. Hum Mol Genet 2000;9(18):2629-37.

Karasneh JA, Hajeer AH, Silman A, Worthington J, Ollier WE, Gul A. Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behçet's disease. Rheumatology (Oxford) 2005;44(5):614-7.

Kara N, Senturk N, Gunes SO, Bagci H, Yigit S, Turanli AY. Lack of evidence for association between endothelial nitric oxide synthase gene polymorphism (Glu298Asp) with Behçet's disease in the Turkish population. Arch Dermatol Res 2006;297(10):468-71.

Oksel F, Keser G, Ozmen M, Aksu K, Kitapcioglu G, Berdeli A, Doganavsargil E. Endothelial nitric oxide synthase gene Glu298Asp polymorphism is associated with Behçet's disease. Clin Exp Rheumatol 2006;24(42):79-82.

Lee YH, Song GG. Associations between eNOS polymorphisms and susceptibility to Behcet's disease: a meta-analysis. J Eur Acad Dermatol Venereol 2012;26(10):1266-71.

Arca E, Gür AR. Behçet hastalığı. T Klin J Med Sci 2003;23:261-8.

Duygulu F, Evereklioglu C, Calis M, Borlu M, Cekmen M, Ascioglu O. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behcet's disease: a pilot study. Clin Rheumatol 2005;24(4):324-30.

Yao L, Romero MJ, Toque HA, Yang G, Caldwell RB, Caldwell RW. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J Cardiovasc Dis Res 2010;1(4):165-70.

Shi J, Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz) 2007;55(2):61- 75.

Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273(37):24266-71.

Oguz E, RhoA/Rho-Kinaz (ROCK) gen polimorfizmlerinin ve ROCK1 ve ROCK2 gen ekspresyonlarının Behçet Hastalığı ile ilişkisinin araştırılması, Gaziantep Üniversitesi, Tıbbi Farmakoloji Anabilim Dalı, Doktora Tezi, 127 sayfa, 2012.

Oguz E, Alasehirli B, Pehlivan Y, Onat AM, Oztuzcu S, Ozkara E, et al. Association between Rho-kinase (ROCK2) gene polymorphisms and Behçet's disease. Transl Res 2012;160(6):428-34.

Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85(6):1504-8.

Gül A, Ozbek U, Oztürk C, Inanç M, Koniçe M, Ozçelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease. Br J Rheumatol 1996;35(11):1178-80.

Oner AF, Gürgey A, Gürler A, Mesci L. Factor V Leiden mutation in patients with Behçet's disease. J Rheumatol 1998;25(3):496-8.

Toydemir PB, Elhan AH, Tükün A, Toydemir R, Gürler A, Tüzüner A, Bökesoy I. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothombin gene G20210A mutations on deep venous thrombogenesis in Behçet's disease. J Rheumatol 2000;27(12):2849-54.

Poort RS, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in 3′-untranslated region of prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698- 703.

Gül A, Aslantas AB, Tekinay T, Koniçe M, Ozçelik T. Procoagulant mutations and venous thrombosis in Behçet's disease. Rheumatology (Oxford) 1999;38(12):1298-9.

Ateş A, Düzgün N, Ulu A, Tiryaki AO, Akar N. Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Behçet's disease. Pathophysiol Haemost Thromb 2003;33(3):157-63.

Monnet E, Sizaret P, Arbeille B, Fauvel-Lafève F. Different role of platelet glycoprotein GP Ia/IIa in platelet contact and activation induced by type I and type III collagens. Thromb Res 2000;98(5):423-33.

Moshfegh K, Wuillemin WA, Redondo M, Lämmle B, Beer JH, Liechti-Gallati S, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999;353(9150):351-4.

Polat G, Eskandari G, Kaya TI, Türsen U, Bagdatoglu O, Ikizoglu G, et al. Association of the platelet glycoprotein Ia C807T/G873A gene polymorphism and thrombosis in Behçet patients. Haematologia (Budap) 2002;32(2):121-8.

Demir HD, Yalçındağ FN, Oztürk A, Akar N. Intron F G79A polymorphism of the protein Z gene in Turkish Behçet patients. Curr Eye Res 2012;37(7):630-2.

Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima- Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 2001;79(10):841-7.

Tursen U, Tamer L, Api H, Yildirim H, Baz K, Ikizoglu G, et al. Cytochrome P450 polymorphisms in patients with Behcet's disease. Int J Dermatol 2007;46(2):153-6.

Aynacioglu AS, Bozkurt A, Nacak M, Kortunay S, Tunc R, Dincel A, et al. N-acetyltransferase polymorphism in patients with Behçet's disease. Eur J Clin Pharmacol 2001;57(9):659-62.

Cooper GS, Treadwell EL, Dooley MA, St Clair EW, Gilkeson GS, Taylor JA. N-acetyl transferase genotypes in relation to risk of developing systemic lupus erythematosus. J Rheumatol 2004;31(1):76-80.